Sumitomo Dainippon Pharma Co Ltd's Fiscal Year is From April To March.
The item "Price-To-Sales-Ratio" stands at 1.41 as of 09/30/2025, the highest value at least since 06/30/2022, the period currently displayed.
As of the end of Sumitomo Dainippon Pharma Co Ltd's second quarter, the item "Price To Sales Ratio" stands at 1.41. This represents an increase of 48.56 percent compared to it's value at the end of it's first quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 95.62 percent compared to the value the year prior.
The 1 year change in percent is 95.62.
The 3 year change in percent is 104.30.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Price To Sales Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Price To Sales Ratio | 486,508,953,600.00 |
![]() | AbbVie Inc - Price To Sales Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Price To Sales Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Price To Sales Ratio | 280,205,508,085.11 |